SEC For	m 4																
FORM 4				UNITED STATES SECURITIES AND EXCHANGE COMMISS Washington, D.C. 20549										OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).						ed pursual	t to Section 16(a) for the In	of the Se	ecuritie		ΗP	Estimated average burden		3235-0287 ien 0.5			
1. Name and Address of Reporting Person [*] Moxham Christopher							er Name and Ticke rum Therapeu				(Chec	5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Own V Officer (give title Other (spe					
(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET							3. Date of Earliest Transaction (Month/Day/Year)								below) ef Scientific Officer		
(Street)				02139		_ 4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		(Sta	ate) Tal	(Zip)	-Deri	vative S	ecurities Acq	uired	Dier		or Bon	aficially	Owned				
1. Title of	T Title of Security (Instr. 3)				2. Tran Date	saction /Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code	action	4. Securities Disposed Of 5)	Acquired	- I (A) or	5. Amount or Securities Beneficially Owned Follo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Reported Transaction((Instr. 3 and			(Instr. 4)	
Common Stock					08/10/2021			M ⁽¹⁾		20,714	Α	\$7.84	20,714	4	D		
Common Stock					08/1	0/2021		S ⁽¹⁾		20,714	D	\$17	0	0 D			
Common			08/10/2021			M ⁽²⁾		31,071	Α	\$7.84	31,07	1	D				
Common Stockm 08/10						.0/2021		S ⁽²⁾		31,071	D	\$ <mark>18</mark>	0		D		
							curities Acqui IIs, warrants,						Dwned				
1. Title of	2.		3. Transaction	3A. Deemed	i i	4.	5. Number 6	. Date E>	ercisa	able and 7.	Title and	Amount 8	3. Price of 9.	Numbe	r of 10.	11. Nature	

Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Da (Month/Day/Y		of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$7.84	08/10/2021		M ⁽¹⁾			20,714	(3)	01/21/2029	Common Stock	20,714	\$0.00	103,572	D	
Stock Option (right to buy)	\$7.84	08/10/2021		M ⁽²⁾			31,071	(3)	01/21/2029	Common Stock	31,071	\$0.00	72,501	D	

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021.

3. The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

Remarks:

/s/ Peter Thomson, as attorney-

in-fact for Christopher

<u>Moxham</u>

** Signature of Reporting Person Date

08/12/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.